Philip J. Mease

76.5k total citations · 19 hit papers
800 papers, 39.2k citations indexed

About

Philip J. Mease is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Philip J. Mease has authored 800 papers receiving a total of 39.2k indexed citations (citations by other indexed papers that have themselves been cited), including 666 papers in Rheumatology, 506 papers in Immunology and 332 papers in Hematology. Recurrent topics in Philip J. Mease's work include Spondyloarthritis Studies and Treatments (572 papers), Psoriasis: Treatment and Pathogenesis (476 papers) and Rheumatoid Arthritis Research and Therapies (400 papers). Philip J. Mease is often cited by papers focused on Spondyloarthritis Studies and Treatments (572 papers), Psoriasis: Treatment and Pathogenesis (476 papers) and Rheumatoid Arthritis Research and Therapies (400 papers). Philip J. Mease collaborates with scholars based in United States, United Kingdom and Canada. Philip J. Mease's co-authors include Dafna D. Gladman, Daniel J. Clauw, Philip Helliwell, I. Jon Russell, Désirée van der Heijde, Don L. Goldenberg, Mary‐Ann Fitzcharles, Anthony S. Russell, William J. Taylor and Christopher T. Ritchlin and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Philip J. Mease

774 papers receiving 38.0k citations

Hit Papers

The American College of R... 2000 2026 2008 2017 2010 2006 2016 2000 2011 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
    2010 2.9k citations Philip J. Mease et al. Arthritis Care & Research profile →
  2. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study
    2006 2.6k citations William J. Taylor, Dafna D. Gladman et al. profile →
  3. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria
    2016 1.4k citations Philip J. Mease et al. profile →
  4. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
    2000 1.1k citations Philip J. Mease et al. profile →
  5. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia
    2011 1.1k citations Philip J. Mease et al. The Journal of Rheumatology profile →
  6. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
    2005 702 citations Philip J. Mease, Dafna D. Gladman et al. profile →
  7. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
    2004 697 citations Philip J. Mease, P A Ory et al. profile →
  8. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 650 citations Iain B. McInnes, Philip J. Mease et al. profile →
  9. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
    2015 572 citations Philip J. Mease, Iain B. McInnes et al. profile →
  10. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
    2008 465 citations Désirée van der Heijde, Robert Landewé et al. profile →
  11. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study
    2009 462 citations Arthur Kavanaugh, Iain B. McInnes et al. profile →
  12. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
    2016 431 citations Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  13. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
    2017 421 citations Philip J. Mease, Oliver FitzGerald et al. profile →
  14. Patient perspectives on the impact of fibromyalgia
    2008 401 citations Philip J. Mease et al. profile →
  15. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
    2014 341 citations Arthur Kavanaugh, Philip J. Mease et al. Annals of the Rheumatic Diseases profile →
  16. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    2020 242 citations Philip J. Mease, Proton Rahman et al. profile →
  17. Psoriatic arthritis
    2021 190 citations Oliver FitzGerald, Alexis Ogdie et al. profile →
  18. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
    2022 134 citations Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →
  19. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
    2023 124 citations Peter Nash, Atul Deodhar et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip J. Mease United States 90 23.4k 19.7k 12.5k 9.0k 6.5k 800 39.2k
Ernest Choy United Kingdom 68 8.3k 0.4× 4.1k 0.2× 3.2k 0.3× 4.2k 0.5× 3.4k 0.5× 352 19.0k
Alfonse T. Masi United States 61 19.5k 0.8× 9.1k 0.5× 2.5k 0.2× 2.6k 0.3× 2.0k 0.3× 206 37.0k
J. W. J. Bijlsma Netherlands 89 15.0k 0.6× 4.0k 0.2× 3.9k 0.3× 1.7k 0.2× 3.4k 0.5× 506 28.8k
Frederick Wolfe United States 76 10.6k 0.5× 2.2k 0.1× 3.0k 0.2× 9.3k 1.0× 7.1k 1.1× 205 24.4k
Tore K Kvien Norway 84 18.4k 0.8× 5.5k 0.3× 5.4k 0.4× 1.8k 0.2× 4.4k 0.7× 537 28.6k
Vibeke Strand United States 73 15.4k 0.7× 6.3k 0.3× 5.6k 0.4× 890 0.1× 1.7k 0.3× 522 22.9k
Piet L. C. M. van Riel Netherlands 69 17.0k 0.7× 5.1k 0.3× 6.3k 0.5× 1.4k 0.2× 966 0.1× 328 24.1k
Gene G. Hunder United States 77 30.3k 1.3× 6.7k 0.3× 4.6k 0.4× 1.9k 0.2× 2.2k 0.3× 217 49.4k
Ronald L. Wilder United States 47 13.8k 0.6× 5.9k 0.3× 3.7k 0.3× 1.4k 0.2× 1.8k 0.3× 113 27.1k
Piercarlo Sarzi‐Puttini Italy 62 5.7k 0.2× 3.0k 0.2× 1.4k 0.1× 5.5k 0.6× 4.0k 0.6× 502 17.0k

Countries citing papers authored by Philip J. Mease

Since Specialization
Citations

This map shows the geographic impact of Philip J. Mease's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Mease with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Mease more than expected).

Fields of papers citing papers by Philip J. Mease

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip J. Mease. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Mease. The network helps show where Philip J. Mease may publish in the future.

Co-authorship network of co-authors of Philip J. Mease

This figure shows the co-authorship network connecting the top 25 collaborators of Philip J. Mease. A scholar is included among the top collaborators of Philip J. Mease based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip J. Mease. Philip J. Mease is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chandran, Vinod, Wilson Liao, Christine A. Lindsay, et al.. (2024). Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatology Advances in Practice. 8(3). rkae074–rkae074. 12 indexed citations
3.
Chen, Daniel, Jingyi Xie, Jongchan Choi, et al.. (2024). Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer. Cell Reports. 43(3). 113872–113872. 4 indexed citations
4.
5.
Mease, Philip J., Dafna D. Gladman, Joseph F. Merola, et al.. (2022). Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. The Journal of Rheumatology. 49(8). 885–893. 13 indexed citations
6.
Mease, Philip J., Iain B. McInnes, Lai‐Shan Tam, et al.. (2021). Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Lara D. Veeken. 60(5). 2109–2121. 42 indexed citations
7.
Deodhar, Atul, Philip J. Mease, Proton Rahman, et al.. (2020). Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. Rheumatology and Therapy. 8(1). 135–150. 11 indexed citations
8.
Coates, Laura C., Joseph F. Merola, Philip J. Mease, et al.. (2020). Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Lara D. Veeken. 60(3). 1137–1147. 11 indexed citations
9.
Orbai, Ana‐Maria, Iain B. McInnes, Laura C. Coates, et al.. (2019). Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. The Journal of Rheumatology. 47(6). 854–864. 13 indexed citations
10.
Mease, Philip J., Dafna D. Gladman, Arthur Kavanaugh, et al.. (2017). Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials. Queensland's institutional digital repository (The University of Queensland). 69. 864–865. 1 indexed citations
11.
Mease, Philip J., et al.. (2017). Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry. The Journal of Rheumatology. 44(2). 184–192. 12 indexed citations
12.
Mease, Philip J., Roy Fleischmann, J. Wollenhaupt, et al.. (2016). CERTOLIZUMAB PEGOL FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA TRIAL. Clinical and Experimental Rheumatology. 34(4). 779–780. 2 indexed citations
13.
Tillett, William, Lihi Eder, Niti Goel, et al.. (2015). Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014. The Journal of Rheumatology. 42(11). 2198–2203. 27 indexed citations
14.
Clark, Michael R., Bill McCarberg, & Philip J. Mease. (2011). Fibromyalgia in primary care: What you need to know now! practical applications for patient care. 11(1). 1–24. 1 indexed citations
15.
Keystone, E., R. Fleischmann, J S Smolen, et al.. (2010). THE EFFICACY OF CERTOLIZUMAB PEGOL ADDED TO METHOTREXATE IS SUSTAINED OVER 2 YEARS IN THE TREATMENT OF RHEUMATOID ARTHRITIS. Lara D. Veeken. 49. 1 indexed citations
16.
Syversen, Silje Watterdal, Robert Landewé, Désirée van der Heijde, et al.. (2009). Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. The Journal of Rheumatology. 36(8). 1769–1784. 12 indexed citations
17.
Keen, Helen, Clifton O. Bingham, Laurence A. Bradley, et al.. (2009). Assessing Single Joints in Arthritis Clinical Trials. The Journal of Rheumatology. 36(9). 2092–2096. 13 indexed citations
18.
Gladman, Dafna D., et al.. (2006). Adalimumab radiographic efficacy in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use, and clinical response: Subanalysis of ADEPT. Research Portal (King's College London). 54(9). 1 indexed citations
19.
Mease, Philip J., John T. Sharp, P A Ory, et al.. (2005). Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: Results from ADEPT. Annals of the Rheumatic Diseases. 64. 320–320. 16 indexed citations
20.
Mease, Philip J., Dafna D. Gladman, Christopher T. Ritchlin, et al.. (2004). Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Research Portal (King's College London). 50(12). 4097–4097. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ernest Choy Breakdown of academic impact, for papers by Alfonse T. Masi Breakdown of academic impact, for papers by J. W. J. Bijlsma Breakdown of academic impact, for papers by Frederick Wolfe Breakdown of academic impact, for papers by Tore K Kvien Breakdown of academic impact, for papers by Vibeke Strand Breakdown of academic impact, for papers by Piet L. C. M. van Riel Breakdown of academic impact, for papers by Gene G. Hunder Breakdown of academic impact, for papers by Ronald L. Wilder Breakdown of academic impact, for papers by Piercarlo Sarzi‐Puttini
Rankless by CCL
2026